Illness due the ebola virus: Epidemiology and clinical manifestations within the context of an international public health emergency;Enfermedad por el virus del Ébola: Epidemiología y manifestaciones clínicas en un contexto de emergencia de salud pública internacional

Revista de Neurologia

Volumn 60, Issue 6, 2015, Pages 267-277

  Carod Artal, Francisco J ^a,b  

^a UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^b RAIGMORE HOSPITAL   (United Kingdom)

Author keywords

Ebolavirus. Ebola virus disease. Epidemiology. Viral hemorrhagic fevers

Indexed keywords

MONOCLONAL ANTIBODY;

ARTICLE; DISEASE ASSOCIATION; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; HEALTH CARE PERSONNEL; HUMAN; INCIDENCE; INCUBATION TIME; MORTALITY; NONHUMAN; PHYSICAL DISEASE BY BODY FUNCTION; PREVALENCE; VIRUS TRANSMISSION; EBOLAVIRUS; EMERGENCY; EPIDEMIC; HEALTH; HEMORRHAGIC FEVER, EBOLA; PATHOGENICITY; PUBLIC HEALTH; TRANSMISSION;

EBOLAVIRUS; EMERGENCIES; EPIDEMICS; GLOBAL HEALTH; HEMORRHAGIC FEVER, EBOLA; HUMANS; PUBLIC HEALTH;

EID: 84924652840     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.6006.2014414     Document Type: Article

References (47)

1. Feldmann H. Ebola -a growing threat? N Engl J Med 2014; 371: 1375-8.
2. Gatherer D. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol 2014; 95: 1619-24.
3. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014; 371: 1418-25.
4. Guenno LB, Galabru J. Ebola virus. Bull Inst Pasteur 1997; 95: 73-83.
5. Bausch DG, Feldmann H, Geisbert TW, Bray M, Sprecher AG, Boumandouki P, et al; Winnipeg Filovirus Clinical Working Group. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. J Infect Dis 2007; 196 (Suppl 2): S136-41.
6. Formenty P, Hatz C, Le Guenno B, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d'Ivoire: clinical and biologic presentation. J Infect Dis 1999; 179 (Suppl 1): S48-53.
7. Barrette RW, Metwally SA, Rowland JM, Xu L, Zaki SR, Nichol ST, et al. Discovery of swine as a host for the Reston ebolavirus. Science 2009; 325: 204-6.
8. World Health Organization. Ebola virus disease update -West Africa. URL: http://www.who.int/csr/disease/ebola/en. [07.09.2014].
9. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers: neglected tropical diseases? PLoS Negl Trop Dis 2012; 6: e1546.
10. Briand S, Bertherat E, Cox P, Formenty P, Kieny MP, Myhre JK, et al. The international Ebola Emergency. N Engl J Med 2014; 371: 1180-3.
11. Outbreaks chronology: ebola hemorrhagic fever. Atlanta: Centers for Disease Control and Prevention. URL: http://www. cdc.gov/vhf/ebola/resources/outbreak-table.html#eighteen. [07.09.2014].
12. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet 2011; 377: 849-62.
13. Groseth A, Feldmann H, Strong JE. The ecology of Ebola virus. Trends Microbiol 2007; 15: 408-16.
14. Georges-Courbot MC, Sanchez A, Lu CY, Baize S, Leroy E, Lansout-Soukate J, et al. Isolation and phylogenetic Introduction. The epidemic caused by the Ebola virus in western Africa affects Guinea, Liberia, Sierra Leone, Nigeria, Mali and Senegal, and is the most serious to occur since the existence of this filovirus, which causes haemorrhagic fever, was first reported. This article reviews the epidemiological characteristics and clinical manifestations associated with the disease due to the Ebola virus. characterization of Ebola viruses causing different outbreaks in Gabon. Emerg Infect Dis 1997; 3: 59-62.
15. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, et al. Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis 2009; 9: 723-8.
16. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009; 5: e1000536.
17. Olival KJ, Hayman DT. Filoviruses in bats: current knowledge and future directions. Viruses 2014; 6: 1759-88.
18. Gupta M, Mahanty S, Greer P, Towner JS, Shieh WJ, Zaki SR, et al. Persistent infection with Ebola virus under conditions of partial immunity. J Virol 2004; 78: 958-67.
19. International Society for Infectious Diseases. Ebola lab accident death-Russia (Siberia), May 22, 2004. Archive number 20040522.1377. http://www.promedmail.org. [07.09.2014].
20. International Society for Infectious Diseases. Ebola virus, needlestick injury -Germany: (Hamburg). March 17, 2009. Archive number 20090317.1084. URL: http://www.promedmail. org. [07.09.2014].
21. Feldmann H. Are we closer to combat Ebola infections? Lancet 2010; 375: 1850-2.
22. Emond RT, Evans B, Bowen ET, Lloyd G. A case of Ebola virus infection. BMJ 1977; 2: 541-4.
23. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis 2004; 4: 487-98.
24. Wong G, Kobinger GP, Qiu X. Characterization of host immune responses in Ebola virus infections. Expert Rev Clin Immunol 2014; 10: 781-90.
25. WHO. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56: 271-93.
26. Breman JG, Piot P, Johnson KM, White MK, Mbuyi M, Sureau P, et al. The epidemiology of Ebola haemorrhagic fever in Zaire, 1976. In Pattyn S, ed. Ebola virus haemorrhagic fever. Amsterdam: Elsevier/North Holland; 1978. p. 103-24.
27. Geisbert TW, Daddario-DiCaprio KM, Williams KJ, Geisbert JB, Leung A, Feldmann F, et al. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola haemorrhagic fever in nonhuman primates. J Virol 2008; 82: 5664-8.
28. Davis KJ, Anderson AO, Geisbert TW, Steele KE, Geisbert JB, Vogel P, et al. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch Pathol Lab Med 1997; 121: 805-19.
29. Roddy P, Howard N, Van Kerkhove MD, Lutwama J, Wamala J, Yoti Z, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, 2007-2008. PLoS One 2012; 7: e52986.
30. Bühler S, Roddy P, Nolte E, Borchert M. Clinical documentation and data transfer from Ebola and Marburg virus disease wards in outbreak settings: health care workers' experiences and preferences. Viruses 2014; 6: 927-37.
31. MacNeil A, Farnon EC, Wamala J, Okware S, Cannon DL, Reed Z, et al. Proportion of deaths and clinical features in Bundibugyo Ebola virus infection, Uganda. Emerg Infect Dis 2010; 16: 1969-72.
32. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med 2014; 371: 2092-100.
33. Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. Neurological complications of dengue virus infection. Lancet Neurol 2013;12: 906-19.
34. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis 1999; 179 (Suppl 1): S28-35.
35. Becquart P, Wauquier N, Mahlakoiv T, Nkoghe D, Padilla C, Souris M, et al. High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon. PLoS One 2010; 5: e9126.
36. Fowler RA, Fletcher T, Fischer WA 2nd, Lamontagne F, Jacob S, Brett-Major D, et al. Caring for critically ill patients with Ebola virus disease: perspectives from West Africa. Am J Respir Crit Care Med 2014; 190: 733-7.
37. Bray M, Paragas J. Experimental therapy of filovirus infections. Antiviral Res 2002; 54: 1-17.
38. Olinger GG Jr, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A 2012; 109: 18030-5.
39. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med 2013; 5: 199ra113.
40. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010; 375: 1896-905.
41. Warren TK, Wells J, Panchal RG, Stuthman KS, Garza NL, Van Tongeren SA, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508: 402-5.
42. Uebelhoer LS, Albarino CG, McMullan LK, Chakrabarti AK, Vincent JP, Nichol ST, et al. High-throughput, luciferase-based reverse genetics systems for identifying inhibitors of Marburg and Ebola viruses. Antiviral Res 2014; 106: 86-94.
43. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514: 47-53.
44. Friedrich BM, Trefry JC, Biggins JE, Hensley LE, Honko AN, Smith DR, et al. Potential vaccines and post-exposure treatments for filovirus infections. Viruses 2012; 4: 1619-50.
45. Frieden TR, Damon I, Bell BP, Kenyon T, Nichol S. Ebola 2014 -new challenges, new global response and responsibility. N Engl J Med 2014; 371: 1177-80.
46. Centers for Disease Control and Prevention. Infection prevention and control recommendations for hospitalized patients with known or suspected Ebola hemorrhagic fever in U.S. hospitals. URL: http://www.cdc.gov/vhf/ebola/hcp/infection-prevention-and-control-recommendations.html. [07.09.2014].
47. Centers for Disease Control and Prevention. Interim guidance about Ebola infection for airline crews, cleaning personnel, and cargo personnel. URL: http://www.cdc.gov/quarantine/ air/managing-sick-travelers/ebola-guidance-airlines.html. [07.09.2014].